Beijing, Shanghai, Boston, Oct 3, 2024 – Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present clinical data of BET inhibitor JAB-8263 at 2024  the 66th ASH (American Society of Hematology) Annual Meeting. 

The ASH Annual Meeting will be held in San Diego, USA from December 7 to 10, 2024. More conference information will be announced after November 5, Eastern Time.

About Jacobio

Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.